T 를 0 办 9 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2022011 | --- | --- | --- | |-------------------------|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | ■特定对象调研 \n□ \n□ 新闻发布会 □ 现场参观 | □ 分析师会议 \n媒体采访 □业绩说明会 \n□ 路演活动 | | | ...

附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 桂林三金药业股份有限公司投资者关系活动记录表 编号：2022009 | --- | --- | --- | --- | |----------------|---------------------------------|--------------------------------------------------|------------| | | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | □ 一对一沟通 | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 华安证券 谭国超、李昌幸、江卉 | | | | 人员姓名 | | | | | 时间 | 2022 年 08 月 30 日 | | | | 地点 | 桂林三金药业股份有限公司会议室 | | | | 上市公司接待人 | 董事长：邹洵 | | | | 员 | 董事会秘书: ...

附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 桂林三金药业股份有限公司投资者关系活动记录表 编号：2022008 | --- | --- | --- | --- | --- | |-------------------|--------------------------------|--------------------------------------------------|------------------------------|-------| | | | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | | | □ 新闻发布会 | □ 路演活动 | | | | | □ 现场参观 | □ 一对一沟通 | | | | | □ 其他 | （请文字说明其他活动内容） | | | | 参与单位名称及 | 东方财富证券 何玮 | 侯伟青 | | | | 人员姓名 | 上海湘楚资产 熊龙启 | | | | | 时间 | 2022 年 08 月 26 日 | | | | | 地点 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2022015 | --- | --- | --- | |-------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ■特定对象调研 | □ 分析师会议 | ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2022014 | --- | --- | |--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | ■特定对象调研 □ 分析师会议 \n媒体采访 □业绩说明会 \n新闻发布会 □ 路演活动 现场参观 | | | □其他（请文字说明其他活动内容） | | 活动参与人员 | 国泰君安证券 蒋文杰、赖立格、李帅中 陆贤 广西银瓴资产管理有限公司 谭亚悦 广东嘉强私募管理有限公司 戴剑辉、何泳彬 上海牧鑫私募基金管理 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2022013 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ■特定对象调研 | □ 分析师会议 | | 投资者关系活动类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □ 现场参观 | □ 路演活动 | | | □其他（请文字说明其他活动内容） | | | 活动参与人员 | 华安证券 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2022012 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | ■特定对象调研 \n□ 媒体采访 □业绩说明会 \n□ 新闻发布会 □ 现场参观 | □ 分析师会议 \n□ 路演活动 | | | □其他（请文字说明其他活动内容） | | | | 东方财富证券 何玮 东方财富 侯伟青 盘京资产 曹珊珊 | 唐佰强 | | 活动参与人员 | 长盛基金 周思聪 桂林三金董事长 邹洵 桂林三 ...

Revenue and Profit - Revenue for Q3 2022 reached ¥443,488,378.21, an increase of 18.03% year-over-year[7] - Net profit attributable to shareholders was ¥21,467,877.53, a decrease of 53.03% compared to the same period last year[7] - Net profit excluding non-recurring gains and losses was ¥14,655,019.81, up 97.43% year-over-year[7] - The company reported a basic earnings per share of ¥0.0281, a decrease of 64.61% compared to the same period last year[7] - The net profit attributable to shareholders of the listed company decreased by 53.03% to CNY 21,467,877.53 compared to the same period last year, primarily due to increased financial expenses and share-based payment provisions[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 97.43% to CNY 14,655,019.81, mainly due to the high non-recurring gains in the previous period from government subsidies[16] - The net profit for the current period is CNY 324,383,259.62, an increase from CNY 292,898,189.25 in the previous period, representing a growth of approximately 10.7%[33] - Operating profit for the current period is CNY 399,141,337.71, compared to CNY 361,237,488.69 in the previous period, indicating an increase of about 10.5%[33] - Total profit for the current period is CNY 395,977,951.32, up from CNY 361,468,249.37, reflecting a growth of approximately 9.5%[33] Assets and Liabilities - Total assets at the end of the period were ¥4,046,301,129.62, a decrease of 1.21% from the end of the previous year[7] - The total assets of the company were CNY 4,046,301,129.62, a decrease from CNY 4,095,868,127.50 at the beginning of the year[30] - The total liabilities amounted to CNY 1,115,823,550.33, down from CNY 1,256,050,962.24[30] - Shareholders' equity attributable to the parent company increased to ¥2,930,477,579.29, up 3.19% from the previous year[7] - The company's equity attributable to shareholders was CNY 2,930,477,579.29, an increase from CNY 2,839,817,165.26[30] Cash Flow - Cash flow from operating activities for the year-to-date was ¥245,023,811.12, down 15.94% year-over-year[7] - Cash received from operating activities decreased by 75.45% to CNY 44,575,648.45, mainly due to a reduction in government subsidies compared to the previous period[16] - Cash paid for purchasing goods and receiving services increased by 93.14% to CNY 418,554,988.76, driven by increased sales and production[16] - Cash received from investment activities increased by 143.56% to CNY 473,707,824.13, mainly due to a higher number of maturing equity instruments[16] - Cash paid for investment activities surged by 1,699.65% to CNY 802,864,785.84, primarily due to increased investments in equity instruments[16] - Net cash flow from operating activities was $245,023,811.12, a decrease of 15.98% compared to $291,495,282.61 in the previous period[41] - Total cash inflow from investment activities was $555,924,903.30, down from $628,619,639.60, reflecting a decrease of 11.56%[41] - Cash outflow from investment activities increased significantly to $974,123,558.30 from $254,862,021.01, indicating a rise of 282.73%[41] - Net cash flow from financing activities was -$175,223,838.83, an improvement from -$295,805,366.73 in the previous period[41] - Cash inflow from financing activities totaled $266,396,014.38, compared to $209,692,691.28 in the previous period, marking an increase of 27.00%[41] - Cash outflow for dividend distribution and interest payments was $333,588,479.24, up from $244,001,210.05, representing a rise of 36.67%[41] Expenses - Management expenses rose by 55.64% to CNY 169,949,093.70, primarily due to the timely recognition of share-based payments[16] - Financial expenses decreased by 63.89% to CNY -5,784,980.30, attributed to increased loan interest and changes in the company's financial structure[16] - Research and development expenses decreased to CNY 127,378,100.62 from CNY 169,712,734.98, a reduction of about 25%[33] - Sales expenses increased to CNY 350,494,315.37 from CNY 309,789,625.49, marking an increase of approximately 13.1%[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,010[19] - The largest shareholder, Guilin Sanjin Group Co., Ltd., holds 62.05% of the shares, totaling 364,586,500 shares[19] Other Information - The company received FDA approval for clinical trials of its subsidiary's drug, indicating potential future growth in the pharmaceutical sector[23] - The company plans to change the purpose of its remaining repurchased shares, totaling 2,631,400 shares, to be used for cancellation to reduce registered capital[24] - The company did not undergo an audit for the third quarter report[44] - Other comprehensive income after tax for the current period is CNY 13,020,354.41, compared to a loss of CNY 1,854,021.31 in the previous period[37] - Basic and diluted earnings per share for the current period are both CNY 0.5547, an increase from CNY 0.5091 in the previous period[37] - The tax expenses for the current period amounted to CNY 71,594,691.70, compared to CNY 68,570,060.12 in the previous period, reflecting an increase of approximately 3%[33]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥995.47 million, representing a 13.13% increase compared to ¥879.90 million in the same period last year[28]. - Net profit attributable to shareholders was approximately ¥302.92 million, an increase of 22.54% from ¥247.19 million in the previous year[28]. - The net profit after deducting non-recurring gains and losses was approximately ¥290.27 million, reflecting a 35.19% increase from ¥214.72 million year-on-year[28]. - The basic earnings per share increased to ¥0.53, up 23.26% from ¥0.43 in the same period last year[28]. - The weighted average return on equity rose to 10.28%, an increase of 2.26% compared to 8.02% in the previous year[28]. - Total assets at the end of the reporting period were approximately ¥4.08 billion, a slight decrease of 0.37% from ¥4.10 billion at the end of the previous year[28]. - Net assets attributable to shareholders increased to approximately ¥2.88 billion, up 1.53% from ¥2.84 billion at the end of the previous year[28]. - The company reported a net cash flow from operating activities of approximately ¥209.39 million, a 4.66% increase from ¥200.07 million in the previous year[28]. - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[6]. Market Environment and Industry Trends - The pharmaceutical manufacturing industry in China saw a revenue of CNY 1,400.78 billion, a year-on-year decrease of 0.60%, with profit totaling CNY 220.95 billion, down 27.60% year-on-year[37]. - The pharmaceutical industry is undergoing a period of adjustment and fluctuation, influenced by policies promoting innovation and strict regulation[37]. - The overall market environment for the pharmaceutical industry is characterized by dual pressures from administrative regulation and market competition[37]. - The company faces risks such as fluctuations in raw material prices and intensified market competition, which investors should be aware of[6]. - The company is facing risks from industry policy changes, particularly related to drug price reductions due to national procurement policies, with an average price drop of 21.8% in certain regions[153]. - The OTC market is expected to face increased competition as prescription drugs transition to non-prescription status, impacting companies focused on OTC products[153]. Product Portfolio and Development - The company holds 218 drug approvals, including 46 unique specialty varieties, with 70 specifications included in the National Essential Medicines List and 113 specifications in the National Medical Insurance Directory[43]. - The company has 64 valid invention patents, including one US invention patent and four patents awarded for excellence in China[43]. - The company aims to strengthen its leadership in the fields of oral and urinary system medications, continuing to grow steadily[40]. - The company has launched a new dosage form of Sanjin Pian, Sanjin Granules, which officially went on sale in 2021[51]. - The company is focused on expanding its product line and enhancing its market presence through innovative product development and strategic partnerships[46]. - The company is committed to ongoing research and development to improve existing products and introduce new therapies to meet market demands[46]. - The company has launched new products, including the Xiguashuang throat lozenge, which has received multiple awards and recognitions, including a national invention patent[55]. - The company is focusing on new product development, particularly in the health food sector, with specific products like Sanjin brand ginseng tablets and other herbal products[147]. Marketing and Sales Strategy - The company has a comprehensive marketing system established across the country, ensuring reliable drug quality and competitive advantages[40]. - The company aims to leverage its strong product portfolio to capture a larger share of the healthcare market, particularly in traditional Chinese medicine[46]. - The company plans to expand its market presence by entering new regions, targeting a 20% increase in market share by the end of 2023[67]. - The company plans to enhance hospital channel development and clinical promotion for its new product "Shu Yan Qing," which has significant market potential[134]. - The company will implement a "one province, one product, one strategy" promotion pilot for second-line exclusive products and continue to replicate and promote third-line exclusive and generic products in other markets[154]. - The company plans to accelerate the nationwide promotion of its value marketing model and optimize channel management to enhance terminal output[154]. Research and Development - The company has invested in R&D projects, including the deep secondary development of SanJin tablets and the development of new biopharmaceuticals[93]. - The company is focusing on research and development of new formulations, with a goal to introduce at least three new products by the end of 2023[67]. - The company is committed to improving cost efficiency across R&D, raw materials, production, and marketing to maintain profitability amid rising competition[153]. Corporate Social Responsibility and Compliance - The company has maintained compliance with environmental standards, with all monitored pollutants meeting the required discharge limits[165]. - The company has established a wastewater treatment system with a daily processing capacity of 2,500 tons, achieving a COD concentration of less than 500 mg/L after treatment[170]. - The company has contributed over 4 million yuan to social responsibility initiatives, including pandemic support and rural revitalization efforts[187]. Operational Challenges and Risk Management - The company has faced operational risks due to the ongoing COVID-19 pandemic and plans to innovate marketing strategies and enhance R&D efforts to mitigate short-term impacts on sales and performance[154]. - The management team has extensive experience and will actively monitor potential risks to ensure the successful completion of the 2022 operational plan and objectives[154]. - The company has faced challenges in the cultivation of raw materials due to environmental factors, impacting the efficiency of the "Modern Chinese Medicine Raw Material GAP Base" project[134]. - The company has successfully modified construction plans to save costs and ensure project completion despite geological challenges[134].